AU Patent

AU2013343425A1 — Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Assigned to Novartis AG · Expires 2015-06-11 · 11y expired

What this patent protects

A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a historic deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a the…

USPTO Abstract

A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a historic deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013343425A1
Jurisdiction
AU
Classification
—
Expires
2015-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.